Pharmaceuticals News

Combined company to operate as Slate Medicines and focus on advancing Slate's portfolio of next-generation migraine therapeutics Slate’s lead product candidate, SLTE-1009, is a clinical stage,...

Key recent and second quarter highlights include: Completed first-cycle FDA review of the Company’s ANDA for preservative-free ketamine with no drug-related major deficiencies. The sole remaining...

– DURAVYU was non-inferior to on-label aflibercept control (nominal p-value = 0.0096) in an ad hoc analysis excluding a 4% asymmetric cohort (9 of 211 patients) who experienced vision loss (≥ 15...

The New Mechanistic Findings Support Can-Fite’s Ongoing Phase IIb Study Design Following Positive Phase IIa Results Ramat Gan, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) --  Can-Fite BioPharma Ltd....

Oslo, 17 August 2026: The Board of Directors of Zelluna ASA (the “Company”) hereby calls for an Extraordinary General Meeting to be held on 9 September 2026 at 13:00 CEST, regarding election of a new...

Oslo, 17 august 2026: Styret i Zelluna ASA («Selskapet») innkaller herved til ekstraordinær generalforsamling som avholdes 9. september 2026 kl 13:00  CEST, vedrørende valg av nytt styremedlem til...

PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL SETTLEMENT AND DELIVERY OF SECURITIES ISSUED AS PART OF ITS €14.2 MILLION PRIVATE PLACEMENT ANNOUNCED ON AUGUST 10, 2026 Paris, August 17, 2026,...

COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE LE SUCCES DU REGLEMENT-LIVRAISON DES TITRES EMIS DANS LE CADRE DE SON PLACEMENT PRIVE DE 14,2 MILLIONS D’EUROS ANNONCE LE 10 AOUT 2026 Paris, 17 août 2026,...

Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011)Patient improvements observed early and sustained...

NEW YORK, Aug. 16, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has completed...